Skip to main content
SpringerLink
Log in

Does Local Therapy for Oligometastatic Disease in Lung Cancer Patients Improve Survival?

  • Chapter
  • First Online:
Difficult Decisions in Thoracic Surgery

Part of the book series: Difficult Decisions in Surgery: An Evidence-Based Approach ((DDSURGERY))

  • 593 Accesses

Abstract

The concept of oligometastasis was introduced nearly 50 years go, but was a rare occurrence in non-small cell lung cancer (NSCLC) until recent years. Now with improved imaging technologies and more efficacious systemic therapies, more patients are presenting with low volume metastatic disease. Aggressive local therapy at the primary and metastatic site have been used for >40 years in NSCLC patient with isolated brain or adrenal metastasis with cure in 10–30%, but without prospective evidence for benefit, its use was not routine and many questioned its true benefit. A recent series of small prospective trials have demonstrated significant survival improvements with local consolidative therapy to all disease sites following first line chemotherapy, and brought this aggressive approach toward local control into the mainstream of care for stage IV NSCLC. In an era when local therapies can be delivered with minimal morbidity and mortality, there is increasing opportunity and evidence for benefit in carefully selected patients with oligometastatic and oligo-progressive NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.

    CAS  PubMed  Google Scholar 

  2. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378–82.

    CAS  PubMed  Google Scholar 

  3. Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares M, Camidge DR. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol. 2009;48(4):578–83.

    CAS  PubMed  Google Scholar 

  4. Eberhardt WE, Mitchell A, Crowley J, Kondo H, Kim YT, Turrisi A 3rd, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the m descriptors in the forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2015;10(11):1515–22.

    PubMed  Google Scholar 

  5. Ashworth AB, Senan S, Palma DA, Riquet M, Ahn YC, Ricardi U, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2014;15(5):346–55.

    PubMed  Google Scholar 

  6. Li D, Zhu X, Wang H, Qiu M, Li N. Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis. J Thorac Dis. 2017;9(2):310–7.

    PubMed  PubMed Central  Google Scholar 

  7. Li S, Zhu R, Li D, Li N, Zhu X. Prognostic factors of oligometastatic non-small cell lung cancer: a meta-analysis. J Thorac Dis. 2018;10(6):3701–13.

    PubMed  PubMed Central  Google Scholar 

  8. Juan O, Popat S. Ablative therapy for oligometastatic non-small cell lung cancer. Clin Lung Cancer. 2017;18(6):595–606.

    PubMed  Google Scholar 

  9. Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):e173501.

    PubMed  Google Scholar 

  12. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051–8.

    PubMed  Google Scholar 

  13. Wronski M, Arbit E, Burt M, Galicich JH. Survival after surgical treatment of brain metastases from lung cancer: a follow-up study of 231 patients treated between 1976 and 1991. J Neurosurg. 1995;83(4):605–16.

    CAS  PubMed  Google Scholar 

  14. Nakagawa H, Miyawaki Y, Fujita T, Kubo S, Tokiyoshi K, Tsuruzono K, et al. Surgical treatment of brain metastases of lung cancer: retrospective analysis of 89 cases. J Neurol Neurosurg Psychiatry. 1994;57(8):950–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280(17):1485–9.

    CAS  PubMed  Google Scholar 

  16. Burt M, Wronski M, Arbit E, Galicich JH. Resection of brain metastases from non-small-cell lung carcinoma. Results of therapy. J Thorac Cardiovasc Surg. 1992;103(3):399–411.

    CAS  PubMed  Google Scholar 

  17. Congedo MT, Cesario A, Lococo F, De Waure C, Apolone G, Meacci E, et al. Surgery for oligometastatic non-small cell lung cancer: long-term results from a single center experience. J Thorac Cardiovasc Surg. 2012;144(2):444–52.

    PubMed  Google Scholar 

  18. Collaud S, Stahel R, Inci I, Hillinger S, Schneiter D, Kestenholz P, et al. Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage. Lung Cancer. 2012;78(3):234–8.

    PubMed  Google Scholar 

  19. Tonnies M, Pfannschmidt J, Bauer TT, Kollmeier J, Tonnies S, Kaiser D. Metastasectomy for synchronous solitary non-small cell lung cancer metastases. Ann Thorac Surg. 2014;98(1):249–56.

    PubMed  Google Scholar 

  20. Downey RJ, Ng KK, Kris MG, Bains MS, Miller VA, Heelan R, et al. A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis. Lung Cancer. 2002;38(2):193–7.

    PubMed  Google Scholar 

  21. Bartlett EK, Simmons KD, Wachtel H, Roses RE, Fraker DL, Kelz RR, et al. The rise in metastasectomy across cancer types over the past decade. Cancer. 2015;121(5):747–57.

    PubMed  Google Scholar 

  22. Salah S, Tanvetyanon T, Abbasi S. Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases: systematic review and analysis of reported cases. Lung Cancer. 2012;75(1):9–14.

    PubMed  Google Scholar 

  23. Kozower BD, Larner JM, Detterbeck FC, Jones DR. Special treatment issues in non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e369S–e99S.

    PubMed  Google Scholar 

  24. Granone P, Margaritora S, D’Andrilli A, Cesario A, Kawamukai K, Meacci E. Non-small cell lung cancer with single brain metastasis: the role of surgical treatment. Eur J Cardiothorac Surg. 2001;20(2):361–6.

    CAS  PubMed  Google Scholar 

  25. Girard N, Cottin V, Tronc F, Etienne-Mastroianni B, Thivolet-Bejui F, Honnorat J, et al. Chemotherapy is the cornerstone of the combined surgical treatment of lung cancer with synchronous brain metastases. Lung Cancer. 2006;53(1):51–8.

    PubMed  Google Scholar 

  26. Furak J, Trojan I, Szoke T, Agocs L, Csekeo A, Kas J, et al. Lung cancer and its operable brain metastasis: survival rate and staging problems. Ann Thorac Surg. 2005;79(1):241–7.

    PubMed  Google Scholar 

  27. Modi A, Vohra HA, Weeden DF. Does surgery for primary non-small cell lung cancer and cerebral metastasis have any impact on survival? Interact Cardiovasc Thorac Surg. 2009;8(4):467–73.

    PubMed  Google Scholar 

  28. Bonnette P, Puyo P, Gabriel C, Giudicelli R, Regnard JF, Riquet M, et al. Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest. 2001;119(5):1469–75.

    CAS  PubMed  Google Scholar 

  29. Billing PS, Miller DL, Allen MS, Deschamps C, Trastek VF, Pairolero PC. Surgical treatment of primary lung cancer with synchronous brain metastases. J Thorac Cardiovasc Surg. 2001;122(3):548–53.

    CAS  PubMed  Google Scholar 

  30. Flannery TW, Suntharalingam M, Regine WF, Chin LS, Krasna MJ, Shehata MK, et al. Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery. Int J Radiat Oncol Biol Phys. 2008;72(1):19–23.

    PubMed  Google Scholar 

  31. Fuentes R, Bonfill X, Exposito J. Surgery versus radiosurgery for patients with a solitary brain metastasis from non-small cell lung cancer. Cochrane Database Syst Rev. 2006;1:CD004840.

    Google Scholar 

  32. Mariya Y, Sekizawa G, Matsuoka Y, Seki H, Sugawara T. Outcome of stereotactic radiosurgery for patients with non-small cell lung cancer metastatic to the brain. J Radiat Res. 2010;51(3):333–42.

    PubMed  Google Scholar 

  33. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v1–v27.

    CAS  PubMed  Google Scholar 

  34. Getman V, Devyatko E, Dunkler D, Eckersberger F, End A, Klepetko W, et al. Prognosis of patients with non-small cell lung cancer with isolated brain metastases undergoing combined surgical treatment. Eur J Cardiothorac Surg. 2004;25(6):1107–13.

    PubMed  Google Scholar 

  35. Cheufou DH, Welter S, Chalvatzoulis E, Christof D, Theegarten D, Stamatis G. Surgery of primary lung cancer with oligometastatic m1b synchronous single brain metastasis: analysis of 37 cases. Thorac Cardiovasc Surg. 2014;62(7):612–5.

    PubMed  Google Scholar 

  36. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552–9.

    PubMed  Google Scholar 

  37. Raz DJ, Lanuti M, Gaissert HC, Wright CD, Mathisen DJ, Wain JC. Outcomes of patients with isolated adrenal metastasis from non-small cell lung carcinoma. Ann Thorac Surg. 2011;92(5):1788–92. Discussion 93.

    PubMed  Google Scholar 

  38. Strong VE, D’Angelica M, Tang L, Prete F, Gonen M, Coit D, et al. Laparoscopic adrenalectomy for isolated adrenal metastasis. Ann Surg Oncol. 2007;14(12):3392–400.

    PubMed  Google Scholar 

  39. Mercier O, Fadel E, de Perrot M, Mussot S, Stella F, Chapelier A, et al. Surgical treatment of solitary adrenal metastasis from non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005;130(1):136–40.

    PubMed  Google Scholar 

  40. Porte H, Siat J, Guibert B, Lepimpec-Barthes F, Jancovici R, Bernard A, et al. Resection of adrenal metastases from non-small cell lung cancer: a multicenter study. Ann Thorac Surg. 2001;71(3):981–5.

    CAS  PubMed  Google Scholar 

  41. Tanvetyanon T, Robinson LA, Schell MJ, Strong VE, Kapoor R, Coit DG, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol. 2008;26(7):1142–7.

    PubMed  Google Scholar 

  42. Luketich JD, Burt ME. Does resection of adrenal metastases from non-small cell lung cancer improve survival? Ann Thorac Surg. 1996;62(6):1614–6.

    CAS  PubMed  Google Scholar 

  43. Aloia TA, Zimmitti G, Conrad C, Gottumukalla V, Kopetz S, Vauthey JN. Return to intended oncologic treatment (RIOT): a novel metric for evaluating the quality of oncosurgical therapy for malignancy. J Surg Oncol. 2014;110(2):107–14.

    PubMed  PubMed Central  Google Scholar 

  44. Wu CT, Lin MW, Hsieh MS, Kuo SW, Chang YL. New aspects of the clinicopathology and genetic profile of metachronous multiple lung cancers. Ann Surg. 2014;259(5):1018–24.

    PubMed  Google Scholar 

  45. Detterbeck FC, Franklin WA, Nicholson AG, Girard N, Arenberg DA, Travis WD, et al. The IASLC Lung Cancer Staging Project: background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(5):651–65.

    PubMed  Google Scholar 

  46. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70(4):606–12.

    CAS  PubMed  Google Scholar 

  47. David EA, Andersen SW, Beckett LA, Melnikow J, Clark JM, Brown LM, et al. Survival benefits associated with surgery for advanced non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019;157(4):1620–8.

    PubMed  Google Scholar 

  48. David EA, Canter RJ, Chen Y, Cooke DT, Cress RD. Surgical management of advanced non-small cell lung cancer is decreasing but is associated with improved survival. Ann Thorac Surg. 2016;102(4):1101–9.

    PubMed  PubMed Central  Google Scholar 

  49. Yang CJ, Gu L, Shah SA, Yerokun BA, D’Amico TA, Hartwig MG, et al. Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: a national analysis. Lung Cancer. 2018;115:75–83.

    PubMed  Google Scholar 

  50. Shen H, Cao Y, Li X, Tan Y, Chen J, Yang Z, et al. Surgical intervention improves survival for metastatic non-small cell lung cancer patients. Medicine (Baltimore). 2016;95(21):e3800.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of Chicago Medicine, Chicago, IL, USA

    Jessica S. Donington

Authors
  1. Jessica S. Donington
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jessica S. Donington .

Editor information

Editors and Affiliations

  1. Department of Surgery, University of Chicago, Chicago, IL, USA

    Mark K. Ferguson

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Donington, J.S. (2020). Does Local Therapy for Oligometastatic Disease in Lung Cancer Patients Improve Survival?. In: Ferguson, M. (eds) Difficult Decisions in Thoracic Surgery. Difficult Decisions in Surgery: An Evidence-Based Approach. Springer, Cham. https://doi.org/10.1007/978-3-030-47404-1_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-47404-1_23

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-47403-4

  • Online ISBN: 978-3-030-47404-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation